Status:
COMPLETED
Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State
Lead Sponsor:
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Conditions:
Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Ketamine is an anaesthetic used in low doses to treat depressive disorders. A related molecule, Esketamine, has recently been launched on the market for the treatment of resistant depression. One of t...
Detailed Description
Patients will be identified when they come for an Esketamine session performed as part of routine practice in the Psychiatry Department of Hôpital Sainte Musse. The clinician, who is also the study in...
Eligibility Criteria
Inclusion
- Patient followed in the Psychiatry Department of Hôpital Sainte Musse, with depressive state characterized by the DSM-V criteria and treated with Esketamine between 2 days and 3 months prior to the study;
- Patient over the age of 18;
- Patient presented transient dissociative state during Esketamine treatment;
- Patient able to express his/her consent prior to participation in the study;
- Patient who understands and speaks French.
Exclusion
- Patient with major anxiety and panic attack during an Esketamine-induced dissociative state, regardless of Esketamine effect;
- Patient under judicial protection (guardianship, curatorship...) or safeguard of justice;
- Pregnant, parturient or breast-feeding women;
- Any other reason that, in the opinion of the investigator, would interfere with the evaluation of the study objectives.
Key Trial Info
Start Date :
March 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06133309
Start Date
March 19 2024
End Date
December 1 2025
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Intercommunal Toulon La Seyne sur Mer
Toulon, Var, France, 83100